The DOI matches its Crossref record.
NONCONTRACEPTIVE ESTROGEN USE AND CARDIOVASCULAR DISEASE
Abstract
To summarize, estrogens have powerful effects on certain biologic parameters, the alteration of which could influence cardiovascular disease risk. Estrogens have long been known to influence lipid and lipoprotein levels by decreasing LDL (the atherogenic lipoprotein) and by increasing HDL (the protective lipoprotein). THese lipid alterations could favorably influence the risk of cardiovascular disease. Estrogens also temporarily increase glucose intolerance and lower fasting glucose levels; although the former event could adversely affect cardiovascular disease risk, the clinical significance of increased glucose intolerance with low fasting levels has not been determined. There is no consistent evidence that menopausal estrogens adversely affect coagulation or blood pressure levels, although both of these parameters could be affected in selected individuals. Overall, the estrogenic effects on lipid/lipoprotein levels appear to be the most consistent and the most powerful; given this assumption, estrogens should protect against cardiovascular disease. There is another interpretation of the biologic effect of estrogens on cardiovascular risk. It is possible that estrogens may increase the risk of a thromboembolic event due to an adverse influence on coagulation parameters and, at the same time, decrease the risk of an atherogenic event (via favorably altered lipid/lipoprotein levels). This proposed dual action of estrogens may explain the apparently conflicting results of increased risks of thromboembolism and decreased risks of atherosclerosis or myocardial infarction in men treated with high doses of estrogen (36, 196, 197). In women, there is some suggestion that (low-dose) postmenopausal estrogens may increase the risk of thromboembolism (79, 204), although the majority of studies report no such increase. The difference in risk of thromboembolism between men and women using estrogens may be due to several factors. First, the dose (potency) of the estrogen used by men is usually higher than that used by postmenopausal women, and the risk of estrogen-induced thrombus formation may be dose-dependent. Second, men tend to have more atherosclerotic lesions than women and thus would have more substrate available for thrombus formation. (This hypothesis is supported by the observation that the increased risk of thromboembolism was evident in men using estrogens for the secondary prevention of cardiovascular disease.) Indirect evidence supporting the hypothesis that endogenous estrogen levels are protective against cardiovascular disease is most consistent for women.(ABSTRACT TRUNCATED AT 400 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Estrogen and coronary heart disease in women
Barrett-Connor, E. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03460140089033 · Cited by 1,241
Self-citationCummings, S. R. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.11.2445 · Cited by 699
A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer
Steinberg, K. K. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03460150089030 · Cited by 626
Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause
Haarbo, J., Marslew, U., Gotfredsen, A., & Christiansen, C. (1991) · Metabolism · doi:10.1016/0026-0495(91)90037-w · Cited by 441
Sex Differences in Physiological Responses to Stress and in Coronary Heart Disease: A Causal Link?
Stoney, C. M., Davis, M. C., & Matthews, K. A. (1987) · Psychophysiology · doi:10.1111/j.1469-8986.1987.tb00264.x · Cited by 336
Metadata
- Authors
- BUSH, T. L., & BARRETT-CONNOR, E.
- Venue
- Epidemiologic Reviews
- Publisher
- Oxford University Press (OUP)
- Published
- 1985
- Volume
- 7
- Issue
- 1
- Pages
- 80-104
- ISSN
- 0193-936X (ISSN-L)
- 1478-6729
- OpenAlex
- W2289584781
- Cited by
- 227
- References
- 0
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NONCONTRACEPTIVE ESTROGEN USE AND CARDIOVASCULAR DISEASE. https://app.cochat.ai/papers/10.1093/oxfordjournals.epirev.a036287
- The paper
- BUSH, T. L., & BARRETT-CONNOR, E. (1985). NONCONTRACEPTIVE ESTROGEN USE AND CARDIOVASCULAR DISEASE. Epidemiologic Reviews. https://doi.org/10.1093/oxfordjournals.epirev.a036287
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.